Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review

Dupuis, Derma; Fritz, Kasinda; Ike, Emeka; Arogundade, Oyinkansola; Adewara, Enoch Oluwalonimi; Monday, Esther O; Ayinde, Bolaji Oluwabusayo

doi:10.7759/cureus.28680

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on a review article, baricitinib was effective in decreasing respiratory failure and the use of mechanical ventilation, also preventing symptoms deterioration. Furthermore, baricitinib as a single agent or combined with other drugs, improved the peripheral capillary oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio ( Dupuis et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

Dastan,

Jamaati,

Barati

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized COVID-19 patients with an inflammatory status. However, the effects of co-administering these medications aiming for more rapid patient recovery are controversial among practitioners. The potential benefits include the rapid improvement of patients and regulation of the immune system, and the potential risks include the increased chance of serious adverse events, including infections. This study aimed to investigate the effects of co-administering these two medications on the 28-day mortality rate, other efficacy parameters, and safety issues.Methods: In this randomized open-label trial, 68 patients were recruited. The study was conducted at Dr. Masih Daneshvari Hospital during 6 months (from 21 March 2022 to 23 August 2022). Severely ill patients aged between 18 and 100 years old with confirmed COVID-19 were enrolled. The primary outcomes included the need for invasive mechanical ventilation and a 28-day mortality rate. Secondary outcomes included the need for non-invasive mechanical ventilation, the need for admission to the intensive care unit (ICU), the length of hospital stay, and the need for a second dose of tocilizumab. Safety assessments were also performed for 28 days. The data were collected from the patients’ medical records, which included age, gender, and comorbidities.Results: The 28-day mortality rate or the need for mechanical ventilation was not statistically different among the two groups (p-value = 0.49 for both outcomes). The need for non-invasive mechanical ventilation, the need for admission to the ICU, or the need for a second dose of tocilizumab and the length of hospital stay was not affected either (p-value = 1; 0.1; 0.49 and 0.9, respectively). One patient developed thrombosis in the combination group. No adverse events related to infectious complications were recorded in any groups.Conclusion: This study showed no beneficial effects of combining tocilizumab and baricitinib in managing severe COVID-19 cases. However, the need for ICU admission was meaningfully lower in the combination group. Studies with larger sample sizes are needed to confirm these results.Clinical Trial Registration: Identifier: RCT20151227025726N30M

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

Dastan,

Jamaati,

Barati

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Recent Trends and Possible Future Trajectory of COVID‐19

Adams,

Adi‐Dako,

Boafo

et al. 2024

Rising Contagious Diseases

View full text Add to dashboard Cite

The Evolution in Pharmacology of Infectious Diseases: 2022

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review

Cited by 4 publications

References 23 publications

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

Recent Trends and Possible Future Trajectory of COVID‐19

The Evolution in Pharmacology of Infectious Diseases: 2022

Contact Info

Product

Resources

About